This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Innova Captab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 of ....
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.1 pts less than Nifty Microcap 250 and 4.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Innova Captab Limited has informed BSE and NSE that its Board of Directors will meet on Monday, May 19, 2025, to consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2025. As per SEBI insider trading rules, the trading window for designated persons and their immediate relatives, which was closed from April 1, 2025, will reopen 48 hours after the results are officially declared. The intimation was signed by Neeharika Shukla, Company Secretary and Compliance Officer.
This is a routine regulatory filing ahead of the FY25 annual results announcement. Investors should watch for the actual results on May 19, which will reveal full-year earnings performance and could drive stock movement once announced.
| Q4 FY25 | Q4 FY24 | Change | |
|---|---|---|---|
| Revenue | ₹314.7 Cr | ₹262.6 Cr | +19.8% |
| Operating profit | ₹35.93 Cr | ₹33.86 Cr | +6.1% |
| Profit after tax | ₹29.57 Cr | ₹28.72 Cr | +3.0% |
| EBITDA margin | 15.2% | 14.5% | +0.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.